Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of KDT-3594 tablets and capsules
jRCT2031260257Phase 1Recruiting
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of matsupexole in Parkinson's disease (PD) (2 arms), sponsored by Kissei Pharmaceutical Co., Ltd. Primary endpoint: Bioequivalence evaluation parameters of plasma KDT-3594 concentrations. Started Jun 2026; status: recruiting.
02
Drugs
matsupexole
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on jRCT2031260257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260257.